Molecular Partners
#8643
Rank
$145.4M
Marketcap
Switzerland
Country
Dr. Patrick Amstutz Ph.D. (Co-Founder, CEO, Member of Management Board & Director)
Dr. Michael Tobias Stumpp Ph.D. (Co-Founder, Exec. VP of Projects & Member of Management Board)
Mr. Andreas Emmenegger E.M.B.A. (Advisor)
Summary
History
Researchers at the University of Zürich, Switzerland formed Molecular Partners AG in 2004 while studying monoclonal antibodies. These scientists discovered and developed the DARPin technology and launched the company using this platform.Molecular Partners became a publicly traded company in November 2014, when it was listed on the SIX Swiss Exchange .Since July 2021, the company is also listed on the Nasdaq in the US under the ticker symbol MOLN.
Mission
Vision
Key Team
Ms. Renate Gloggner (Exec. VP of People & Community and Member of Management Board)
Mr. Alexander Zurcher (COO & Member of Management Board)
Dr. Nicolas Leupin M.B.A., Ph.D., M.D., MBA (Chief Medical Officer & Member of Management Board)
Mr. Daniel Steiner Ph.D. (Sr. VP of Research)
Mr. Seth D. Lewis (Sr. VP of Investor Relations, Communications & Strategy)
Mr. Michael Pitzner (Gen. Counsel, Compliance Officer & Sr. VP of Legal)
Mr. Thomas Schwerzmann (VP of HR)
Recognition and Awards
References
Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.
Dr. Patrick Amstutz Ph.D. (Co-Founder, CEO, Member of Management Board & Director)
Dr. Michael Tobias Stumpp Ph.D. (Co-Founder, Exec. VP of Projects & Member of Management Board)
Mr. Andreas Emmenegger E.M.B.A. (Advisor)